Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254157 | ENERGETIC CANCER STEM CELLS (E-CSCS): A NEW HYPER-METABOLIC AND PROLIFERATIVE TUMOR CELL PHENOTYPE, DRIVEN BY MITOCHONDRIAL ENERGY | December 2020 | April 2022 | Allow | 16 | 2 | 0 | Yes | No |
| 17009410 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC LAG3 | September 2020 | September 2022 | Allow | 24 | 4 | 0 | Yes | No |
| 17003081 | MODIFIED CELLS AND METHODS OF THERAPY | August 2020 | January 2023 | Allow | 28 | 7 | 0 | Yes | No |
| 16996103 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | August 2020 | April 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 16983937 | Antigen Discovery for T Cell Receptors Isolated from Patient Tumors Recognizing Wild-Type Antigens and Potent Peptide Mimotopes | August 2020 | October 2021 | Abandon | 14 | 2 | 0 | No | No |
| 16924950 | ENGINEERED REGULATORY T CELLS | July 2020 | July 2021 | Allow | 13 | 2 | 1 | Yes | No |
| 16958649 | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | June 2020 | February 2023 | Allow | 31 | 3 | 1 | Yes | No |
| 16904451 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS | June 2020 | June 2021 | Allow | 12 | 2 | 1 | Yes | No |
| 16881668 | BCMA-TARGETED CHIMERIC ANTIGEN RECEPTOR AS WELL AS PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | May 2020 | July 2021 | Allow | 14 | 1 | 0 | Yes | No |
| 15929513 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS | May 2020 | June 2021 | Allow | 13 | 2 | 1 | Yes | No |
| 16864689 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN | May 2020 | December 2021 | Abandon | 19 | 3 | 0 | No | No |
| 16818211 | TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES | March 2020 | November 2023 | Abandon | 44 | 5 | 1 | No | No |
| 16631437 | SINGLE CHAIN VH AND HEAVY CHAIN ANTIBODIES | January 2020 | March 2022 | Allow | 26 | 2 | 1 | Yes | No |
| 16742723 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN | January 2020 | September 2021 | Abandon | 20 | 2 | 1 | No | No |
| 16709147 | DELIVERY OF PACKAGED RNA TO MAMMALIAN CELLS | December 2019 | December 2023 | Abandon | 48 | 1 | 0 | No | No |
| 16707807 | QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES | December 2019 | July 2021 | Allow | 19 | 4 | 0 | Yes | No |
| 16708082 | QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES | December 2019 | May 2021 | Allow | 17 | 4 | 0 | Yes | No |
| 16613025 | GENERATING MAMMALIAN T CELL ACTIVATION INDUCIBLE SYNTHETIC PROMOTERS (SYN+PRO) TO IMPROVE T CELL THERAPY | November 2019 | August 2023 | Allow | 45 | 1 | 1 | Yes | No |
| 16656322 | ACTIVITY MODULATOR, MEDICINAL AGENT COMPRISING SAME, USE OF CD300A GENE-DEFICIENT MOUSE, AND ANTI-CD300A ANTIBODY | October 2019 | May 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16593832 | ELECTROPHYSIOLOGICALLY MATURE CARDIOMYOCYTES AND METHODS FOR MAKING SAME | October 2019 | April 2023 | Abandon | 43 | 0 | 1 | No | No |
| 16588357 | Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy | September 2019 | May 2022 | Allow | 31 | 0 | 0 | Yes | No |
| 16588591 | Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy | September 2019 | May 2022 | Allow | 32 | 2 | 0 | Yes | No |
| 16579235 | HUMAN PLURIPOTENT ADULT STEM CELLS | September 2019 | August 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16563422 | Anti-Tumor Properties of Dickkopf 3b | September 2019 | April 2022 | Allow | 31 | 2 | 0 | Yes | No |
| 16551337 | CELL CHARACTERISATION | August 2019 | March 2023 | Abandon | 43 | 2 | 1 | No | No |
| 16546202 | HIGH SPEED MOLECULAR SENSING WITH NANOPORES | August 2019 | October 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16540673 | MULTIPARTITE SIGNALING PROTEINS AND USES THEREOF | August 2019 | April 2022 | Abandon | 32 | 1 | 1 | No | No |
| 16484948 | COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION | August 2019 | December 2022 | Allow | 40 | 1 | 1 | Yes | No |
| 16534344 | Fully-human T-cell receptor specific for the 369-377 epitope derived from the Her2/Neu (ERBB2) receptor protein. | August 2019 | February 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16530981 | MULTI-FUNCTION AND MULTI-TARGETING CAR SYSTEM AND METHODS FOR USE THEREOF | August 2019 | October 2023 | Abandon | 50 | 1 | 2 | Yes | No |
| 16529159 | ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLS | August 2019 | May 2021 | Allow | 22 | 4 | 1 | Yes | No |
| 16529251 | ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLS | August 2019 | June 2020 | Allow | 11 | 1 | 1 | Yes | No |
| 16529029 | QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIES | August 2019 | January 2021 | Allow | 17 | 4 | 0 | Yes | No |
| 16526353 | Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion | July 2019 | January 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16455077 | METHODS AND COMPOSITIONS FOR DECREASING CHRONIC PAIN | June 2019 | May 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16474426 | CHIMERIC ANTIGEN RECEPTOR AND NATURAL KILLER CELLS EXPRESSING SAME | June 2019 | July 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16446522 | Coordinating Gene Expression Using RNA Destabilizing Elements | June 2019 | May 2020 | Allow | 11 | 1 | 0 | Yes | No |
| 16446505 | Coordinating Gene Expression Using RNA Destabilizing Elements | June 2019 | April 2020 | Allow | 10 | 1 | 0 | Yes | No |
| 16443405 | METHODS FOR SYSTEMICALLY DELIVERING POLYPEPTIDES AND MICROORGANISMS THEREFOR | June 2019 | March 2022 | Abandon | 33 | 2 | 1 | Yes | No |
| 16442274 | T CELL-ANTIGEN COUPLER WITH VARIOUS CONSTRUCT OPTIMIZATIONS | June 2019 | March 2020 | Allow | 9 | 1 | 0 | Yes | No |
| 16469553 | CHIMERIC ANTIGEN RECEPTOR GENE-MODIFIED LYMPHOCYTE HAVING CYTOCIDAL EFFECT | June 2019 | July 2023 | Abandon | 49 | 2 | 1 | Yes | No |
| 16466327 | STABLY ENGINEREED PROTEASOME INHIBITOR RESISTANT IMMUNE CELLS FOR IMMUNOTHERAPY | June 2019 | May 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16462492 | COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS | May 2019 | August 2023 | Allow | 51 | 3 | 1 | Yes | No |
| 16395896 | RECOMBINANT NUCLEIC ACIDS ENCODING COSMETIC PROTEIN(S) FOR AESTHETIC APPLICATIONS | April 2019 | May 2020 | Allow | 12 | 2 | 1 | Yes | No |
| 16343951 | AP4 AND METHODS OF PROMOTING T CELL ACTIVATION | April 2019 | March 2023 | Allow | 47 | 3 | 1 | No | No |
| 16389821 | HUMANIZED MOUSE MODEL | April 2019 | December 2022 | Allow | 44 | 2 | 1 | Yes | No |
| 16379610 | COMPOSITIONS AND METHODS RELATING TO MYOMAKER-INDUCED MUSCLE CELL FUSION | April 2019 | May 2022 | Allow | 37 | 1 | 1 | Yes | No |
| 16340085 | IMMUNOTHERAPY METHODS AND COMPOSITIONS INVOLVING TRYPTOPHAN METABOLIC PATHWAY MODULATORS | April 2019 | September 2023 | Allow | 54 | 4 | 1 | Yes | No |
| 16371501 | CHIMERIC ANTIGEN RECEPTORS (CARs) TARGETING HEMATOLOGIC MALIGNANCIES, COMPOSITIONS AND METHODS OF USE THEREOF | April 2019 | June 2023 | Abandon | 51 | 3 | 1 | Yes | No |
| 16354098 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | March 2019 | January 2023 | Abandon | 46 | 2 | 1 | No | No |
| 16330307 | IMMUNE CELLS DERIVED FROM INDUCED PLURIPOTENT STEM CELL | March 2019 | July 2022 | Allow | 41 | 2 | 1 | Yes | No |
| 16272679 | Coordinating Gene Expression Using RNA Destabilizing Elements | February 2019 | May 2021 | Allow | 27 | 4 | 1 | Yes | No |
| 16322584 | PRODUCTION OF MEGAKARYOCTYE COMPOSITIONS AND THERAPIES FOR TREATMENT OF THROMBOCYTOPENIA | February 2019 | November 2021 | Abandon | 34 | 2 | 1 | Yes | No |
| 16256436 | LIVE BACTERIAL VACCINES RESISTANT TO CARBON DIOXIDE (CO2), ACIDIC PH AND/OR OSMOLARITY FOR VIRAL INFECTION PROPHYLAXIS OR TREATMENT | January 2019 | September 2022 | Abandon | 44 | 2 | 1 | Yes | No |
| 16255348 | CHIMERIC ANTIGEN RECEPTORS TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III | January 2019 | October 2021 | Allow | 33 | 1 | 1 | Yes | No |
| 16245828 | MRNA THERAPY FOR PHENYLKETONURIA | January 2019 | February 2022 | Allow | 37 | 2 | 1 | Yes | No |
| 16312794 | PLURIPOTENT STEM CELL AND T CELL DIFFERENTIATED THEREFROM AND APPLICATION THEREOF | December 2018 | February 2022 | Allow | 38 | 1 | 1 | Yes | No |
| 16312769 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF | December 2018 | September 2022 | Abandon | 45 | 1 | 1 | No | No |
| 16195586 | INTRACELLULAR OSTEOPONTIN REGULATES THE LINEAGE COMMITMENT OF LYMPHOID SUBSETS | November 2018 | February 2022 | Allow | 39 | 1 | 1 | Yes | No |
| 16192178 | ORGAN REGENERATION METHOD UTILIZING iPS CELL AND BLASTOCYST COMPLEMENTATION | November 2018 | October 2021 | Abandon | 35 | 1 | 1 | No | No |
| 16182808 | NOVEL BT TOXIN RECEPTORS AND METHODS OF USE | November 2018 | October 2021 | Abandon | 35 | 1 | 1 | No | No |
| 16179364 | Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy | November 2018 | May 2019 | Allow | 7 | 1 | 0 | Yes | No |
| 16094247 | ANTI-ROBO1 CAR-T CELL, AND PREPARATION AND APPLICATION THEREOF | October 2018 | March 2022 | Allow | 41 | 2 | 1 | Yes | No |
| 16159517 | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF | October 2018 | June 2022 | Abandon | 44 | 2 | 1 | No | No |
| 16092837 | METHODS FOR CREATING SYNTHETIC CHROMOSOMES EXPRESSING BIOSYNTHETIC PATHWAYS AND USES THEREOF | October 2018 | February 2023 | Allow | 52 | 2 | 1 | Yes | No |
| 16148783 | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | October 2018 | September 2020 | Allow | 24 | 3 | 0 | Yes | No |
| 16135222 | RECOMBINANT ADENO-ASSOCIATED VIRUS DELIVERY OF ALPHA-SARCOGLYCAN POLYNUCLEOTIDES | September 2018 | January 2022 | Allow | 40 | 2 | 0 | Yes | No |
| 16128558 | Modified Bacteriophage | September 2018 | September 2022 | Allow | 48 | 2 | 1 | Yes | No |
| 16083661 | Methods of Preserving Mesenchymal Stem Cells | September 2018 | January 2023 | Allow | 52 | 3 | 1 | Yes | No |
| 16083503 | Mesoderm Induction Method Having High Blood Cell Differentiation Capacity | September 2018 | July 2021 | Allow | 34 | 1 | 1 | Yes | No |
| 16082929 | CULTURE MEDIUM COMPOSITION FOR SUSPENSION CULTURE ALLOWING EASY CELL RECOVERY, AND CELL RECOVERY METHOD | September 2018 | October 2021 | Allow | 38 | 2 | 1 | Yes | No |
| 16082691 | TUMOR CELL SUSPENSION CULTURES AND RELATED METHODS | September 2018 | March 2023 | Allow | 54 | 3 | 1 | Yes | No |
| 16120055 | NIPAH VIRUS ENVELOPE PSEUDOTYPED LENTIVIRUSES AND METHODS OF THEIR USE | August 2018 | September 2022 | Allow | 49 | 3 | 1 | Yes | No |
| 15998685 | Integrated methods for precision manufacturing of tissue engineering scaffolds | August 2018 | March 2021 | Allow | 31 | 1 | 1 | Yes | No |
| 16074539 | Methods for Generation of Cell-derived Microfilament Network | August 2018 | August 2021 | Allow | 37 | 3 | 1 | Yes | No |
| 16048676 | MicroRNAS FOR THE GENERATION OF ASTROCYTES | July 2018 | February 2021 | Abandon | 30 | 0 | 1 | No | No |
| 16049041 | DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS TO MULTIPOTENT NEURAL CREST CELLS | July 2018 | February 2022 | Abandon | 42 | 2 | 1 | No | No |
| 16046083 | Compositions and Methods of Delivering Treatments for Latent Viral Infections | July 2018 | March 2021 | Abandon | 32 | 1 | 0 | No | No |
| 16073297 | COMPOSITION FOR INDUCING BEIGE ADIPOCYTE DIFFERENTIATION CONTAINING EXOSOME DERIVED FROM STEM CELLS | July 2018 | March 2021 | Allow | 31 | 1 | 1 | Yes | No |
| 16037942 | METHODS AND COMPOSITIONS FOR MODIFICATION OF A HLA LOCUS | July 2018 | August 2020 | Allow | 25 | 0 | 0 | Yes | No |
| 16036638 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | July 2018 | January 2021 | Abandon | 30 | 0 | 1 | No | No |
| 16026199 | METHODS AND COMPOSITIONS FOR DETACHING ADHERENT CELLS | July 2018 | August 2021 | Abandon | 38 | 2 | 0 | Yes | No |
| 16026539 | CELL CULTURE PROCESS FOR MAKING A GLYCOPROTEIN | July 2018 | September 2021 | Abandon | 39 | 2 | 1 | No | No |
| 16018435 | METHOD FOR PRODUCING CONTINUOUS CELL LINES | June 2018 | January 2021 | Abandon | 31 | 1 | 0 | No | No |
| 16015159 | GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX ANIMALS | June 2018 | May 2020 | Allow | 23 | 3 | 1 | Yes | No |
| 16007928 | MINIMAL VOLUME REPROGRAMMING OF MONONUCLEAR CELLS | June 2018 | November 2020 | Allow | 29 | 1 | 0 | Yes | No |
| 16061091 | GENE THERAPY FOR COMBINED METHYLMALONIC ACIDEMIA/ACIDURIA AND HYPERHOMOCYSTEINEMIA/HOMOCYSTINURIA, COBALAMIN C TYPE, AND DEFICIENCY OF MMACHC | June 2018 | July 2022 | Allow | 49 | 2 | 1 | Yes | No |
| 16005645 | GENE KNOCKOUT METHOD BASED ON BASE EDITING AND ITS APPLICATION | June 2018 | December 2021 | Allow | 42 | 2 | 1 | Yes | No |
| 16060252 | IMMORTALISED CHICKEN EMBRYONIC EPITHELIAL KIDNEY CELLS | June 2018 | June 2021 | Abandon | 36 | 2 | 1 | No | No |
| 16002604 | EXPRESSION OF HIV INHIBITORS BY MESENCHYMAL STEM CELLS | June 2018 | February 2022 | Allow | 44 | 4 | 1 | Yes | No |
| 15996271 | Method For Inducing Antitumor Immunity Using Sindbis Viral Vectors And Tumor Associated Antigens | June 2018 | March 2021 | Abandon | 34 | 1 | 1 | No | No |
| 15991833 | GENERATION OF HUMAN MACROPHAGES IN IMMUNODEFICIENT NON-HUMAN HOSTS | May 2018 | April 2021 | Abandon | 35 | 1 | 1 | No | No |
| 15779578 | METHOD FOR MANUFACTURING MESENCHYMAL CELL LINE DERIVED FROM VERTEBRATE ANIMAL ADIPOSE TISSUE | May 2018 | July 2022 | Allow | 50 | 3 | 1 | Yes | No |
| 15935768 | CELL TISSUE GEL CONTAINING COLLAGEN AND HYALURONAN | March 2018 | October 2021 | Abandon | 42 | 2 | 1 | No | No |
| 15934177 | IN VITRO PRODUCTION OF RED BLOOD CELLS WITH SORTAGGABLE PROTEINS | March 2018 | October 2021 | Allow | 43 | 2 | 1 | Yes | No |
| 15934770 | Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy | March 2018 | May 2019 | Allow | 14 | 2 | 0 | Yes | No |
| 15927007 | GENETIC METHOD TO KILL CANCER CELLS BY SUFFOCATION | March 2018 | December 2019 | Abandon | 21 | 2 | 1 | No | No |
| 15927040 | TREATING CANCER WITH CAS ENDONUCLEASE COMPLEXES | March 2018 | May 2021 | Abandon | 38 | 2 | 1 | No | No |
| 15759501 | IMMUNOGENIC ANTIGEN IDENTIFICATION FROM A PATHOGEN AND CORRELATION TO CLINICAL EFFICACY | March 2018 | May 2021 | Allow | 39 | 2 | 1 | Yes | No |
| 15916446 | COMPOSITIONS AND METHODS FOR BACTERIAL DELIVERY OF POLYPEPTIDES | March 2018 | December 2020 | Abandon | 34 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LEAVITT, MARIA GOMEZ.
With a 62.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner LEAVITT, MARIA GOMEZ works in Art Unit 1633 and has examined 736 patent applications in our dataset. With an allowance rate of 44.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner LEAVITT, MARIA GOMEZ's allowance rate of 44.2% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by LEAVITT, MARIA GOMEZ receive 2.21 office actions before reaching final disposition. This places the examiner in the 57% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by LEAVITT, MARIA GOMEZ is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +66.7% benefit to allowance rate for applications examined by LEAVITT, MARIA GOMEZ. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.4% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 33.6% of cases where such amendments are filed. This entry rate is in the 52% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 18.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 78.4% of appeals filed. This is in the 70% percentile among all examiners. Of these withdrawals, 75.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 75.3% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.